🚀 VC round data is live in beta, check it out!
- Public Comps
- Vicapsys
Vicapsys Valuation Multiples
Discover revenue and EBITDA valuation multiples for Vicapsys and similar public comparables like Labiana Health, Zhengye Biotechnology, Cynata Therapeutics, Annovis Bio and more.
Vicapsys Overview
About Vicapsys
Vicapsys Life Sciences Inc is a biotech company that is engaged in commercializing implantable medical products that incorporate VICAPSYN, inducing a zone of immuno-protection around devices and cells implanted in the human body. The product VICAPSYN is the company's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field.
Founded
1997
HQ

Employees
2
Website
Sectors
Financials (FY)
EV
$48M
Vicapsys Financials
Vicapsys reported last fiscal year revenue of — and negative EBITDA of ($1M).
In the same fiscal year, Vicapsys generated ($1M) in EBITDA losses and had net loss of ($1M).
Vicapsys P&L
In the most recent fiscal year, Vicapsys reported revenue of — and EBITDA of ($1M).
Vicapsys expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($1M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($1M) | XXX | XXX | XXX |
| Net Debt | — | — | $344K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Vicapsys Stock Performance
Vicapsys has current market cap of $47M, and enterprise value of $48M.
Market Cap Evolution
Vicapsys' stock price is $1.46.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $48M | $47M | 0.0% | XXX | XXX | XXX | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVicapsys Valuation Multiples
Vicapsys trades at (41.1x) EV/EBITDA.
Vicapsys Financial Valuation Multiples
As of April 11, 2026, Vicapsys has market cap of $47M and EV of $48M.
Equity research analysts estimate Vicapsys' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vicapsys has a P/E ratio of (40.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $47M | XXX | $47M | XXX | XXX | XXX |
| EV (current) | $48M | XXX | $48M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (41.1x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (45.6x) | XXX | XXX | XXX |
| P/E | — | XXX | (40.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (114.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vicapsys Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Vicapsys Margins & Growth Rates
Vicapsys' revenue in the last fiscal year grew by —.
Vicapsys' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.
Vicapsys Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Vicapsys Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Labiana Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhengye Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Annovis Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vicapsys M&A Activity
Vicapsys acquired XXX companies to date.
Last acquisition by Vicapsys was on XXXXXXXX, XXXXX. Vicapsys acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Vicapsys
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVicapsys Investment Activity
Vicapsys invested in XXX companies to date.
Vicapsys made its latest investment on XXXXXXXX, XXXXX. Vicapsys invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Vicapsys
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vicapsys
| When was Vicapsys founded? | Vicapsys was founded in 1997. |
| Where is Vicapsys headquartered? | Vicapsys is headquartered in United States. |
| How many employees does Vicapsys have? | As of today, Vicapsys has over 2 employees. |
| Is Vicapsys publicly listed? | Yes, Vicapsys is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of Vicapsys? | Vicapsys trades under VICP ticker. |
| Who are competitors of Vicapsys? | Vicapsys main competitors are Labiana Health, Zhengye Biotechnology, Cynata Therapeutics, Annovis Bio. |
| What is the current market cap of Vicapsys? | Vicapsys' current market cap is $47M. |
| Is Vicapsys profitable? | No, Vicapsys is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.